Look back at pharma news in the week to May 22, 2020

24 May 2020

By Barbara Obstoj-Cardwell. Editor

UK-based AstraZeneca last week announced an up to $1 billion award from the USA’s BARDA to support the development and production of the investigational COVID-19 vaccine candidate AZD 1222, formerly dubbed ChAdOx1 nCoV-19. Also on the novel coronavirus scene, US biotech Sorrento Therapeutics presented strong findings from a trial of its STI-1499, part of the firm’s COVID-19 program, and US biotech Moderna saw its shares rocket after revealing positive results from a clinical trial of its COVID-19 candidate mRNA-1273. Meantime, HIV specialist ViiV Healthcare presented positive interim analysis of the HIV Prevention Trials Network 083 study. Regulatory news included AstraZeneca and partner Merck & Co gaining another US indication approved for its already blockbuster drug Lynparza, now in mCRPC, a type of prostate cancer.

AstraZeneca moves to upstage Moderna in COVID-19 vaccines

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK